In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
NEW YORK (Reuters Health) – Reduced-dose chemotherapy in children with Down syndrome (DS) associated acute myeloid leukemia or myelodysplastic syndrome effectively maintains survival, researchers report in a March…
NEW YORK (Reuters Health) – Empiric therapy in extremely low birth weight (ELBW) infants with invasive Candida infections is associated with improved outcomes (less death and neurodevelopmental impairment),…
NEW YORK (Reuters Health) – Transplacental sotalol, alone or in combination with digoxin, is effective for the treatment of fetal supraventricular tachyarrhythmia (SVT) and atrial flutter, with rapid…
NEW YORK (Reuters Health) – An investigational formulation of azelastine and fluticasone (MP29-02) is more effective than either agent alone as intranasal therapy for moderate-to-severe seasonal allergic rhinitis…
NEW YORK (Reuters Health) – The investigational GLP-1 receptor antagonist lixisenatide significantly reduces postprandial glucose excursions and HbA1c in patients with type 2 diabetes who have not been…
NEW YORK (Reuters Health) – Results of two trials indicate that verteporfin photodynamic therapy plus ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularization…
NEW YORK (Reuters Health) – Administration of epinephrine or vasopressin to patients in cardiac arrest improves short-term survival, but has no benefit over the longer term, according to…
NEW YORK (Reuters Health) – Among patients undergoing invasive coronary angiography or PCI with the use of low-osmolar contrast media (LOCM), adverse outcomes are uncommon with no advantage…
NEW YORK (Reuters Health) – Most prostate cancers detected after more than two biopsies turn out to be clinically insignificant, according to a report from the Cleveland Clinic,…
NEW YORK (Reuters Health) – In a European study, patients at high risk of recurrent gastrointestinal stromal tumor (GIST) who received imatinib (Gleevec; Novartis) for three years after…
